KRAS and non-small cell lung carcinoma: As of April 2024, two KRAS G12C inhibitors have been approved by the FDA, including sotorasib and adagrasib, as a subsequent line of treatment for KRAS G12C mutated non-small cell lung cancer (NSCLC).